SCA
SRPT icon

Spearhead Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Spearhead Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,259
Closed -$244K – 152
2022
Q2 		$244K Sell
3,259
-50
-2% -$3.68K 0.04% 148
2022
Q1 		$258K Sell
3,309
-1,875
-36% -$144K 0.03% 160
2021
Q4 		$467K Buy
5,184
+52
+1% +$4.45K 0.06% 105
2021
Q3 		$475K Sell
5,132
-27
-0.5% -$2.08K 0.06% 102
2021
Q2 		$401K Buy
5,159
+847
+20% +$64.2K 0.05% 139
2021
Q1 		$321K Buy
4,312
+2,370
+122% +$219K 0.05% 151
2020
Q4 		$331K Buy
1,942
+71
+4% +$10.5K 0.05% 134
2020
Q3 		$263K Buy
1,871
+113
+6% +$17.2K 0.05% 149
2020
Q2 		$282K Buy
+1,758
New +$239K 0.06% 113

Other funds holding SRPT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Spearhead Capital Advisors's SRPT Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 3,259 shares — an estimated $244K sold.

Spearhead Capital Advisors first reported a position in SRPT in Q2 2020 and held it in 9 quarters. The position peaked at $475K in Q3 2021. 376 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 3,259 Sarepta Therapeutics shares in Q3 2022, an estimated $244K.
  • Spearhead Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 9 quarters.
  • Spearhead Capital Advisors's Sarepta Therapeutics position peaked at $475K in Q3 2021.
  • 376 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.